Top-Rated StocksTop-RatedNASDAQ:DMRA Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis $18.74 +0.31 (+1.68%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Damora Therapeutics, Inc. Common Stock Stock (NASDAQ:DMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DMRA alerts:Sign Up Key Stats Today's Range$17.84▼$18.8950-Day Range$18.43▼$32.4452-Week Range$4.95▼$38.33Volume357,623 shsAverage Volume429,168 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$46.50Consensus RatingBuy Company Overview Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. Read More Damora Therapeutics, Inc. Common Stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreDMRA MarketRank™: 3.263426107405 of 5 starsDamora Therapeutics, Inc. Common Stock scored higher than 65% of companies evaluated by MarketBeat, and ranked 307th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDamora Therapeutics, Inc. Common Stock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDamora Therapeutics, Inc. Common Stock has a consensus price target of $46.50, representing about 148.1% upside from its current price of $18.74.Amount of Analyst CoverageDamora Therapeutics, Inc. Common Stock has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Damora Therapeutics, Inc. Common Stock's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Damora Therapeutics, Inc. Common Stock are expected to decrease in the coming year, from ($2.06) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.70% of the float of Damora Therapeutics, Inc. Common Stock has been sold short.Short Interest Ratio / Days to CoverDamora Therapeutics, Inc. Common Stock has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Damora Therapeutics, Inc. Common Stock has recently increased by 0.02%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDamora Therapeutics, Inc. Common Stock does not currently pay a dividend.Dividend GrowthDamora Therapeutics, Inc. Common Stock does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.71 News SentimentDamora Therapeutics, Inc. Common Stock has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Damora Therapeutics, Inc. Common Stock this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for DMRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Damora Therapeutics, Inc. Common Stock to their MarketBeat watchlist in the last 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $252,875.00 in company stock, which represents 0.0219% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Damora Therapeutics, Inc. Common Stock insiders have bought more of their company's stock than they have sold. Specifically, they have bought $252,875.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.40% of the stock of Damora Therapeutics, Inc. Common Stock is held by insiders.Percentage Held by Institutions14.20% of the stock of Damora Therapeutics, Inc. Common Stock is held by institutions.Read more about Damora Therapeutics, Inc. Common Stock's insider trading history. Receive DMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Damora Therapeutics, Inc. Common Stock and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMRA Stock News HeadlinesDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Raised to Hold at Wall Street ZenOctober 11, 2026 | americanbankingnews.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 15 at 1:00 AM | Chaikin Analytics (Ad)Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC FilingSeptember 29, 2026 | marketscreener.comMInsider Buying: Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Acquires $252,875.00 in StockSeptember 29, 2026 | insidertrades.comDamora Therapeutics: Potential Payday Is A Long Way OffSeptember 15, 2026 | seekingalpha.comDAMORA THERAPEUTICS INCSeptember 12, 2026 | finanznachrichten.deDamora Therapeutics Grants Inducement Awards To Three New EmployeesSeptember 3, 2026 | rttnews.comSee More Headlines DMRA Stock Analysis - Frequently Asked Questions How have DMRA shares performed this year? Damora Therapeutics, Inc. Common Stock's stock was trading at $23.01 on January 1st, 2026. Since then, DMRA shares have decreased by 18.6% and is now trading at $18.74. How were Damora Therapeutics, Inc. Common Stock's earnings last quarter? Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.06. When did Damora Therapeutics, Inc. Common Stock's stock split? Damora Therapeutics, Inc. Common Stock's stock reverse split on the morning of Friday, August 30th 2024.The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Damora Therapeutics, Inc. Common Stock? Shares of DMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Damora Therapeutics, Inc. Common Stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Damora Therapeutics, Inc. Common Stock investors own include Palantir Technologies (PLTR), Tesla (TSLA), NVIDIA (NVDA), Alibaba Group (BABA), Joby Aviation (JOBY), Pinterest (PINS) and Archer Aviation (ACHR). Company Calendar Last Earnings8/10/2026Today10/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DMRA's financial health is in the Green zone, according to TradeSmith. DMRA has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DMRA Previous SymbolNASDAQ:GLTO CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Damora Therapeutics, Inc. Common Stock$46.50 High Price Target$60.00 Low Price Target$40.00 Potential Upside/Downside+148.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-176.39% Return on Assets-77.86% Debt Debt-to-Equity RatioN/A Current Ratio19.73 Quick Ratio19.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($110.11) per share Price / Book-0.17Miscellaneous Outstanding Shares61,740,000Free Float61,489,000Market Cap$1.16 billion OptionableNo Data Beta1.43 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:DMRA) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Damora Therapeutics, Inc. Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Damora Therapeutics, Inc. Common Stock With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
